Intrexon will take the name of its subsidiary. That company just scored orphan status for a rare cancer drug.
Just four days after Intrexon Corp. (NASDAQ: XON) made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment.
Germantown’s Precigen Inc. has earned orphan drug status from the Food and Drug Administration for its therapy for relapsed or refractory acute myeloid leukemia, a form of cancer in the blood and bone marrow, in cases that have either come back or failed to respond to past treatment. The company … (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 6, 2020 Category: Biotechnology Authors: Sara Gilgore Source Type: news
Brentuximab Vedotin with Re-induction Chemotherapy Effective, Well Tolerated in AML
A phase I study showed brentuximab vedotin combined with a standard chemotherapy regimen of mitoxantrone, etoposide, and cytarabine may be safe and well tolerated in patients with relapsed/refractory acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - January 3, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news
Closer to identifying leukemic stem cells
(Josep Carreras Leukaemia Research Institute) Researchers at the Josep Carreras Leukaemia Research Institute have developed innovative diagnostic trials to identify cells resistant to leukemia treatment. These new trials allow the identification of a subgroup of patients with an unfavorable prognosis at the time of diagnosis of acute myeloid leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 2, 2020 Category: International Medicine & Public Health Source Type: news
AML Highlights From the 2019 ASH Annual Meeting AML Highlights From the 2019 ASH Annual Meeting
Dr Harry Erba reviews several studies presented at the ASH 2019 annual meeting that have practice-changing implications for treating acute myeloid leukemia.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 30, 2019 Category: Consumer Health News Tags: None ReCAP Source Type: news
Artificial intelligence tracks down leukemia
(DZNE - German Center for Neurodegenerative Diseases) Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability. Researchers at the DZNE and the University of Bonn have now shown this in a proof-of-concept study. Their approach is based on the analysis of the gene activity of cells found in the blood. Used in practice, this approach could support conventional diagnostics and possibly accelerate the beginning of therapy. The research results have been published in the journal 'iScience'. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2019 Category: Cancer & Oncology Source Type: news
Acute leukemia patients treated with common therapy have increased risk for heart failure
(University of Pennsylvania School of Medicine) Patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) who are treated with anthracyclines are at a heightened risk of heart failure -- most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine. To help identify a patient's risk for heart failure following the treatment, researchers developed a risk score (0 to 21) based on clinical and echographic variables. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2019 Category: Cancer & Oncology Source Type: news
Oral Azacitidine: First Maintenance Therapy for AML Oral Azacitidine: First Maintenance Therapy for AML
A new oral formulation of azacitidine (CC-486) significantly improved overall survival when used as maintenance therapy in patients with acute myeloid leukemia (AML).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Research revises classification of acute myeloid leukemia & myelodysplastic syndrome
(St. Jude Children's Research Hospital) Findings presented as a late-breaking abstract at the American Society of Hematology annual meeting by St. Jude Children's Research Hospital showcase the power and potential of combining genomic and transcriptomic data. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2019 Category: Cancer & Oncology Source Type: news
No Decreased Survival in Blacks With AML Compared With Whites No Decreased Survival in Blacks With AML Compared With Whites
Although blacks with acute myeloid leukemia were more likely to have evidence of abnormal kidney function, the excess of this comorbidity didn ' t affect overall survival, compared with whites.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 5, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Acute Myeloid Leukemia and Antifungal Prophylaxis Era: Compliance of AML Centers, Invasive Fungal Infection (IFI) Classification, IFI Incidence and AML Outcomes from ALFA 2007- 02 Study
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 5, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Survival Benefits from Antifungal Prophylaxis and a Dedicated Inpatient Malignant Hematology Service during Induction Chemotherapy for Acute Myeloid Leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - December 5, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Phase I/II Studies of Annamycin in Acute Myeloid Leukemia Report Positive Interim Results
Additional positive interim safety and efficacy data were reported for annamycin in the treatment of patients with relapsed or refractory acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 4, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Impact of Invasive Aspergillosis occuring during remission-induction therapy on outcome of Acute Myeloid Leukemia (SEIFEM 2012B Study).
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 12, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
Retrospective analysis of invasive aspergillosis in pediatric patients with acute myeloid leukemia
Conference abstracts (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 12, 2019 Category: Respiratory Medicine Authors: MeganB Source Type: news
